We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

Repurposing Anti-TNF for Treating Dupuytren's Disease (RIDD)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03180957
Recruitment Status : Completed
First Posted : June 8, 2017
Last Update Posted : April 20, 2021
Department of Health, United Kingdom
Wellcome Trust
180 Therapeutics LP
Information provided by (Responsible Party):
University of Oxford

Brief Summary:

Dupuytren's disease is a very common condition, affecting 4% of the general UK and US population. It causes the fingers to curl irreversibly into the palm and can be extremely disabling. The disease usually starts as a small firm lump (nodule) in the palm, and in about 40% of patients advances to form cords that pull the fingers into the palm. There is no approved treatment for the early stage of disease. Once patients have established deformities, the diseased tissue can removed by surgery or cut using less invasive techniques such as a needle or an enzyme. However, recovery following surgery usually takes several months and recurrence rates with the less invasive techniques are high.

The investigators have unravelled the cellular process that initiates and maintains the disease progress and identified tumour necrosis factor (TNF) as a new target for treatment. Based on these findings the investigators plan to test the effects of adalimumab, an anti-TNF drug which currently approved for use in patients with rheumatoid arthritis and other inflammatory conditions. The aim of the study is to find out whether treatment by injection with adalimumab directly into the diseased tissue will control the advance of early Dupuytren's disease better than a placebo injection with normal saline.

The investigators will first carry out a small trial in up to 40 patients with established disease to determine the best dose that reduces the activity of the cells responsible for the disorder (Dose Response study). In this part patients who will be having surgery to remove their diseased tissue will receive a single injection of adalimumab into the nodule in their hand about 2 weeks before surgery. The tissue that is then removed during surgery will be analysed in the investigator's laboratories to determine the effect of the drug on the tissue. Patients will be followed for 12 weeks after surgery.

In the second part of the study the investigators will assess whether the optimal dose of the drug prevents early disease advancing in 138 patients (Early Disease study). Patients who take part in the second part of the study will receive a total of 4 injections of adalimumab into the nodule in their hand at three monthly intervals. They will then be checked at 3 & 9 months after the last injection. In additional to assessing the effect of the injections on the nodule and hand function, information will also be collected to assess the cost effectiveness of the treatment.

Condition or disease Intervention/treatment Phase
Dupuytren's Disease Drug: Adalimumab Drug: Saline Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 209 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Masking Description: During Dose Response part of the trial the Investigator will be blinded. During the Early Disease part of the trial the Investigator will not be blinded but will not carry out any outcome assessments.
Primary Purpose: Treatment
Official Title: A Multi-centre, Double Blind, Randomised, Placebo-controlled, Parallel Group, Phase II Trial to Determine the Efficacy of Intra-nodular Injection of Anti-TNF to Control Disease Progression in Early Dupuytren's Disease, With a Dose Response.
Actual Study Start Date : March 2, 2016
Actual Primary Completion Date : November 2020
Actual Study Completion Date : December 2020

Resource links provided by the National Library of Medicine

Drug Information available for: Adalimumab

Arm Intervention/treatment
Experimental: Anti-TNF
Drug: Adalimumab
Other Name: Humira

Placebo Comparator: Placebo
Drug: Saline

Primary Outcome Measures :
  1. Dose Response: expression of mRNA for α-SMA [ Time Frame: Analysis of tissue removed at 12-18 days post-treatment ]
  2. Early Disease: change in nodule hardness between baseline at 12 months [ Time Frame: 12 months ]

Secondary Outcome Measures :
  1. Dose Response: expression of mRNA for COL-1A1, COL-3A1, cadherin 11 [ Time Frame: Analysis of tissue removed at 12-18 days post-treatment ]
  2. Dose Response: Levels of α-SMA and collegen protein [ Time Frame: Analysis of tissue removed at 12-18 days post-treatment ]
  3. Dose Response: Nodule hardness [ Time Frame: 2 weeks post treatment ]

  4. Dose Response: Visual comparison of surgical wounds using hand photographs [ Time Frame: 2 weeks post surgery ]
  5. Dose Response & Early Disease: Change in nodule size and vascularity from baseline [ Time Frame: 2 weeks post treatment (dose response) / 18 months (early disease) ]
    Pixel analysis of ultrasound imaging

  6. Dose Response and Early Disease: participant injection experience [ Time Frame: Baseline (Dose response) / 12 months (early disease) ]
    Numeric rating scale of pain

  7. Dose Response & Early Disease: Adverse event assessment [ Time Frame: 2 weeks (dose response) / 12 months (early disease) ]
    Assessment of the injection site for pre-specified Adverse Events; surgery site assessment (Dose response only): wound assessment criteria, Centres for Disease Control and Prevention.

  8. Early Disease: Nodule hardness [ Time Frame: 18 months post treatment ]

  9. Early Disease: range of motion of the affected digit [ Time Frame: 18 months ]
    Goniometer reading

  10. Early Disease: Grip strength [ Time Frame: 18 months ]
    Jamar meter

  11. Early Disease: patient reported outcomes [ Time Frame: 18 months ]
    Michigan Hand Outcomes Questionnaire

  12. Early Disease: patient reported outcomes [ Time Frame: 18 months ]
    Participant identified activity most restricted by DD scored on a scale of 1-10

  13. Early Disease: progression to surgery of the digit being assessed [ Time Frame: 18 months ]

Other Outcome Measures:
  1. Dose Response & Early Disease: Circulating levels of adalimumab in the blood [ Time Frame: 2 weeks (dose response) / 12 months (early disease) ]
  2. Dose Response & Early Disease: Circulating levels of antibodies to adalimumab in the blood [ Time Frame: 2 weeks (dose response) / 12 months (early disease) ]
  3. Dose Response: Acceptability of the injection and return to paid work [ Time Frame: 12 weeks post-surgery ]
    Patient-completed questionnaire: numeric rating scale

  4. Early Disease: Cost effectiveness [ Time Frame: 18 months ]
    EQ-5D-5L data

  5. Early disease: Analysis of resource use data [ Time Frame: 18 months ]
    Patient completed questionnaire about health & social care and financial costs of Dupuytren's disease

  6. Dose Response & Early Disease: Exploratory Objective: Investigation of newly identified relevant molecular markers [ Time Frame: Dose Response: 12-18 days post treatment (tissue)/ 2 weeks post treatment (blood). Early Disease: 3 & 12 months post 1st treatment (blood) ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Participant is willing and able to give informed consent for participation in the study.
  • Male or Female, aged 18 years or above.
  • For Part 1: Diagnosed with DD affecting the fingers resulting in flexion deformities of ≥30° at the metacarpophalangeal joint and or the proximal interphalangeal joint with impaired hand function and awaiting surgery. Or for Part 2: Participants with early disease nodules who have shown or reported progression of the disease in the previous 6 months with flexion deformities of their fingers of ≤30° at the metacarpophalangeal and/or at the proximal interphalangeal joint, i.e. total flexion deformity of up to 60°.
  • The DD nodule to be treated must be distinct and identifiable.
  • Female participants of child bearing potential, and male participants whose partner is of child bearing potential, must be willing to ensure that they or their partner use effective contraception throughout the treatment period and for 5 months following the last research injection. Acceptable methods of contraception include: a combination of male condom with either cap, diaphragm or sponge with spermicide (double barrier methods), injectables, the combined oral contraceptive pill (at a stable dose for at least 3 months before entering the study), an intrauterine device, vasectomised partner, or true sexual abstinence (when this is in line with the preferred and usual lifestyle of the participant).
  • Participant results from safety screening tests within normal ranges within 12 weeks of enrolment, with the exception that an earlier clear chest x-ray result may be used where this is in accordance with the time frames of local standard procedures for anti-TNF screening.
  • Able (in the Investigators opinion) and willing to comply with all study requirements.
  • Willing to allow his or her general practitioner to be notified of participation in the study.
  • Sufficient language fluency to ensure informed consent is obtained and to complete the questionnaires pertaining to hand function.

Exclusion Criteria:

  • For Part 1: Participant has previously had fasciectomy, dermofasciectomy, needle fasciotomy, collagenase injection, steroid injection or radiotherapy to treat Dupuytren's disease in the digit concerned. Or for Part 2: Participant has previously had fasciectomy, dermofasciectomy, needle fasciotomy, collagenase injection, steroid injection to the digit to be treated or radiotherapy to treat Dupuytren's disease in the hand concerned.
  • Female participant who is pregnant, lactating or planning pregnancy during the course of the study and for 5 months following last injection.
  • Male participant who is planning a pregnancy during the course of the study and for 5 months following last injection.
  • Significant renal or hepatic impairment.
  • For Part 1: Scheduled elective surgery or other procedures requiring general anaesthesia during the study other than the scheduled Dupuytren's surgery. Or for Part 2: Scheduled elective surgery or other procedures requiring general anaesthesia during the study
  • Participant who has ever been diagnosed with cancer, is terminally ill or is inappropriate for placebo medication
  • Systemic inflammatory disorder such as rheumatoid arthritis (RA) or inflammatory bowel disease.
  • Any other significant disease or disorder which, in the opinion of the Investigator, may either put the participants at risk because of participation in the study, or may influence the result of the study, or the participant's ability to participate in the study.
  • Participated in another research study involving an investigational medicinal product in the past 12 weeks.
  • Known allergy to any anti-TNF agent.
  • Have HIV or hepatitis B or C.
  • Known to have an infection or history of repeated infections.
  • History of Tuberculosis (TB).
  • Have Multiple Sclerosis (MS) or other demyelinating disease.
  • History of local injection site reactions.
  • Needle phobia.
  • Have moderate or severe heart failure.
  • Part 1: Being treated with coumarin anticoagulants, such as warfarin.
  • Have known lung fibrosis (thickening of lung tissue).
  • Being treated with concomitant biologic DMARDS.
  • Have received a live vaccine within the previous 4 weeks. Participants may receive concurrent vaccinations but must avoid the use of live vaccines for 12 weeks after their last injection.
  • Part1: Have received parenteral steroid within the previous 6 weeks.
  • Part 2: Participants at risk of Hepatitis B infection.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03180957

Layout table for location information
The University Medical Centre
Groningen, Netherlands, 9700 RB
United Kingdom
NHS Lothian
Edinburgh, United Kingdom, EH1 3EG
Oxford University Hospitals NHS Foundation Trust
Oxford, United Kingdom, OX3 9DU
Sponsors and Collaborators
University of Oxford
Department of Health, United Kingdom
Wellcome Trust
180 Therapeutics LP
Layout table for investigator information
Principal Investigator: Jagdeep Nanchahal, PhD FRCS University of Oxford
Additional Information:
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: University of Oxford
ClinicalTrials.gov Identifier: NCT03180957    
Other Study ID Numbers: 11069
HICF-R8-433 ( Other Grant/Funding Number: Health Innovation Challenge Fund )
2015-001780-40 ( EudraCT Number )
ISRCTN27786905 ( Registry Identifier: ISRCTN )
15/SC/0259 ( Other Identifier: UK Health Research Authority )
CTU0028 ( Other Identifier: OCTRU )
First Posted: June 8, 2017    Key Record Dates
Last Update Posted: April 20, 2021
Last Verified: October 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by University of Oxford:
anti TNF
phase II clinical trial
randomized controlled trial
double-blind method
Dupuytren's contracture
Additional relevant MeSH terms:
Layout table for MeSH terms
Dupuytren Contracture
Neoplasms, Fibrous Tissue
Neoplasms, Connective Tissue
Neoplasms, Connective and Soft Tissue
Neoplasms by Histologic Type
Muscular Diseases
Musculoskeletal Diseases
Connective Tissue Diseases
Anti-Inflammatory Agents
Antirheumatic Agents